Low cost drug development in BRICS countries
Our efforts aim to change the landscape of care by alleviating the oxygen dependency due to respiratory symptoms. In many rural areas, there is no way to combat the logistic nightmare of filling tanks during a global pandemic to satisfy rural areas. Hospital beds are in short supply in small communities surrounding major city centers.
This simple logistic problem is one of many reasons respiratory diseases plague low income demographic areas, as well as high transportation fees associated with travel from major city centers.
Over the next five years, Oxybreathe is expected to transition from clinical development to becoming a leading low-cost respiratory therapy with global reach. In the first two years, the focus will remain on completing Phase II trials and advancing into Phase III, while expanding research collaborations and initiating early access programs in underserved regions.
By the third year, regulatory submissions are anticipated in the United States, Europe, and key emerging markets, supported by strategic licensing and manufacturing scale-up agreements.
In the fourth year, Oxybreathe is projected to achieve initial market entry, targeting populations with limited access to affordable respiratory care and hospitals seeking cost-effective alternatives. At this stage, revenues could surpass $500 million, driven by rapid adoption in cost-sensitive markets.
By the fifth year, Oxybreathe is expected to secure approvals across all major markets, reaching annual revenues exceeding $2 billion and establishing itself as the global leader in accessible respiratory therapies.
Beyond commercial success, Oxybreathe will deliver significant social impact by reducing hospitalization rates and improving the quality of life for millions of patients worldwide, while providing investors with strong returns through sustainable growth and market leadership.
India
The pharmaceutical industry in India was valued at an estimated US$50 billion in FY 2023-24 and is estimated to reach $130 billion by 2030.
India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world.
Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.
Brazil
Brazil is the only Latin American country ranking among the top pharmaceutical markets worldwide, with a global share of approximately two percent, and a revenue of more than 20 billion USD. In fact, the South American country has one of the fastest growth rates among leading pharmaceutical markets in the world, with an estimated nine percent increase in 2023, and a pharmaceutical industry that has been increasingly growing in recent years.
More than any other industry, the pharmaceutical sector is highly dependent on scientific research and development.
Clinical trials are a crucial step in the process of new drugs becoming available on the market. Brazil is the Latin American country where the highest number of clinical trials have been performed, with over 10,000 studies recorded as of February 2025.
That year, most clinical studies conducted in the country were in phase 3, with more than 3,000. More than half of the total had already been completed.
Overall, the pharmaceutical market in Brazil is expected to expand, with revenue forecast to consistently increase in the coming years. Estimates indicate that this value could rise by 20 percent in the next five years, reaching close to 26 billion U.S. dollars by 2029.
Russia
The Russian pharmaceutical industry stands today as a formidable paradox: a market demonstrating robust growth in local currency, yet one shaped by profound geopolitical pressures and an unwavering state-led campaign for technological sovereignty.
Valued at over 2.8 trillion roubles and projected to exceed 3 trillion, it is an arena of immense opportunity and equally significant complexity.
For any business professional, investor, or strategist looking to navigate this terrain, understanding its unique dynamics is not just an advantage it is a prerequisite for survival and success.
At the heart of this transformation is the “Pharma 2030” strategy, an ambitious industrial policy that functions as the market’s central organizing principle. More than a set of goals, it is a doctrine aimed at fundamentally re-engineering the industry away from import dependency and towards full-cycle domestic production, from the synthesis of Active Pharmaceutical Ingredients (APIs) to the manufacturing of finished drugs.
This state-driven imperative has ignited a paradigm shift, creating a new competitive landscape where success is defined not just by innovation or market share, but by strategic alignment with national priorities.
